Design Therapeutics, Inc. Interest Receivable, Current
Design Therapeutics, Inc. (DSGN) had Interest Receivable, Current of $1.79 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes
us-gaap:InterestReceivableCurrent · last filed 2026-08-03
- 2026-06-30: Interest Receivable, Current $1.79M.
- 2026-03-31: Interest Receivable, Current $1.82M.
- 2025-12-31: Interest Receivable, Current $1.68M.
- 2025-09-30: Interest Receivable, Current $1.38M.
| Period end | Interest Receivable, Current |
|---|---|
| 2026-06-30 | $1.79M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $1.82M 10-Q · filed 2026-04-28 |
| 2025-12-31 | $1.68M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $1.38M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.35M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.41M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $1.26M 10-K · filed 2026-03-09 |
| 2024-09-30 | $1.18M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.40M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $1.68M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $1.43M 10-K · filed 2025-03-10 |
| 2023-09-30 | $1.21M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $994.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $974.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $1.11M 10-K · filed 2024-03-19 |
| 2022-09-30 | $746.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $691.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $100.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $110.00K 10-K · filed 2023-03-14 |
| 2021-09-30 | $47.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $76.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $27.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | $10.00K 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |